MetaCap

Virax Biolabs Group Limited (VRAX)

NASDAQ: VRAXHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD

0.3319-0.0491 (-12.89%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

VRAX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$446.40K
EPS (TTM)
-$12.64
52-week range
0.293 – 21.75
Day range
0.3287 – 0.3696
Volume / Avg
85.67K / 360.62K
Beta
—

52-week range

$0.293$21.75

VRAX stock today

Shares of Virax Biolabs Group (VRAX) finished lower on Nov 20 at $0.3319, a drop of 12.89% or $0.0491 per share, versus the S&P 500's 3.70% decline. Trading was light, with 85.67K shares changing hands, about 24% of the average daily volume. Shares are 98.5% below their 52-week high of $21.75 and 13.3% above the 52-week low of $0.293, near the bottom of the past year's range.

Virax Biolabs Group has posted a net loss over the last twelve months (EPS of -$12.64), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Virax Biolabs Group

Company profile

Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease. It also provides ImmuneSelect, a research-use-only portfolio of peptide pool ELISpot plates and related immune reagents.

Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
CEO
Mr. James Foster
Headquarters
Lanarkshire
Employees
26
IPO year
2022

Financial highlights

Full financials

In fiscal 2025, Virax Biolabs Group generated $6,331 in revenue, down 96.0% from fiscal 2024, its first annual decline since 2022. Virax Biolabs Group reported a net loss of $6.1 million, compared with a loss of $6.7 million a year earlier. Gross margin was -838.2% (down from 32.3%) and operating margin -97344.8%.

Virax Biolabs Group annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$6.33K$156.42K$8.56K$0$123.82K
Growth-95.95%+1727.11%—-100.00%—
Net income$-6.06M$-6.73M$-5.46M$-1.71M$-650.98K
EPS (diluted)$-1.62$-3.36$-5.13$-1.79—

VRAX news

All VRAX news

Virax Biolabs Group peers

Health Care sector
VRAX peer companies
CompanyPrice% ChgMarket capCompare
QCLSQ/C Technologies Inc.0.2784-6.01%$2.40Mvs VRAX
CDIOCardio Diagnostics Holdings Inc.1.60-3.03%$4.74Mvs VRAX
BMRABiomerica Inc.1.08-0.92%$4.97Mvs VRAX
TRIBTrinity Biotech plc ADR6.24+13.76%$5.07Mvs VRAX
VNRXVolitionRX Limited0.1621-1.58%$5.85Mvs VRAX
IMDXInsight Molecular Diagnostics Inc.1.97+18.67%$80.88Mvs VRAX
ICCCImmuCell Corporation10.92-2.41%$99.28Mvs VRAX
NNNNAnbio Biotechnology Class A3.32-9.04%$145.72Mvs VRAX

Indexes, lists and sector

Virax Biolabs Group stock FAQ

What is Virax Biolabs Group's stock price today?

VRAX last traded at $0.3319 as of Nov 20, 4:00 PM EST, down 12.89% on the day. Prices are delayed at least 15 minutes.

Who is Virax Biolabs Group's CEO?

Mr. James Foster is the chief executive officer of Virax Biolabs Group Limited, which has about 26 employees.

What is the VRAX 52-week high?

The 52-week high for VRAX is $21.75 and the 52-week low is $0.293. The stock is currently 98.5% below its high.

Compare VRAX